Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 13, 1999
Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indicesH W Woitge, M Pecherstorfer, Y Li, et al.
The Clinical Investigator|July 1, 1994
High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failureM Pecherstorfer, I Zimmer-Roth, S Weidinger, et al.
Anticancer Research|September 1, 1994
pS2 protein status fails to be an independent prognostic factor in an average breast cancer populationP Speiser, J Stolzlechner, K Haider, et al.
British Journal of Cancer|March 18, 2004
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesJ J Body, I J Diel, M Lichinitzer, et al.
British Journal of Cancer|January 1, 1997
Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patientsN Zojer, M Fiegl, J Angerler, et al.
Cancer|December 1, 1995
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapyH Ludwig, E Sundal, M Pecherstorfer, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1996
Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone diseaseM J Seibel, H W Woitge, M Pecherstorfer, et al.
Klinische Wochenschrift|October 2, 1991
[Pamidronate in the treatment of tumor-associated hypercalcemia]M Pecherstorfer, S Janisch, C Marosi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2008
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label studyR von Moos, C B Caspar, B Thürlimann, et al.
Bone|February 1, 1996
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancyA Sauty, M Pecherstorfer, I Zimmer-Roth, et al.
Pageof 4